Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v8-FR | Version v7-EN | |
---|---|---|
Language | French | English |
Date Updated | 2022-11-02 | 2022-11-02 |
Drug Identification Number | 02244622 | 02244622 |
Brand name | MILRINONE LACTATE INJECTION, USP | MILRINONE LACTATE INJECTION, USP |
Common or Proper name | MILRINONE LACTATE INJECTION, USP | MILRINONE LACTATE INJECTION, USP |
Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
Ingredients | MILRINONE | MILRINONE |
Strength(s) | 1MG | 1MG |
Dosage form(s) | SOLUTION | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
Packaging size | 20mL | 20mL |
ATC code | C01CE | C01CE |
ATC description | CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES | CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES |
Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
Anticipated start date | 2022-08-01 | 2022-08-01 |
Actual start date | 2022-08-01 | 2022-08-01 |
Estimated end date | 2022-10-31 | 2022-10-31 |
Actual end date | 2022-11-01 | 2022-11-01 |
Shortage status | Resolved | Resolved |
Tier 3 Status | No | No |
Company comments | Fresenius Kabi Canada regrets to advise that due to a production delay, we will be facing a supply interruption on our Milrinone Lactate Injection 1 mg/mL SD Vial 20 mL effective August 1, 2022 until October 31, 2022. Contract customers will be allocated 100% of historical monthly demand of the 10 mL plus 100% of the 20 mL on a mL per mL basis. Allocations for August will be prorated for the remainder of the month, which equates to 50% of monthly allocations. Effective September 1, 2022, contract customers will have access to their full monthly allocations. | Fresenius Kabi Canada regrets to advise that due to a production delay, we will be facing a supply interruption on our Milrinone Lactate Injection 1 mg/mL SD Vial 20 mL effective August 1, 2022 until October 31, 2022. Contract customers will be allocated 100% of historical monthly demand of the 10 mL plus 100% of the 20 mL on a mL per mL basis. Allocations for August will be prorated for the remainder of the month, which equates to 50% of monthly allocations. Effective September 1, 2022, contract customers will have access to their full monthly allocations. |
Health Canada comments |